A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Conjunctivitis, Allergic

Interventions

DRUG: Alcaftadine 0.25%
DRUG: Olopatadine 0.2%
DRUG: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%

Sponsor

Allergan